Juan Bueno

Juan Bueno

Auto-generated profile, based on publicly available information

Juan Bueno

Research Center of Bioprospecting and Biotechnology for Biodiversity Foundation (BIOLABB)

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2009 in Clinical and Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
JBJ. G. Bueno
J. G. Bueno
CMCatalina Martinez-Jaramillo
Catalina Martinez-Jaramillo
BZB. Zapata
B. Zapata
GSG. Sanclemente
G. Sanclemente
MGM. Gallego
M. Gallego
AMA. C. Mesa
A. C. Mesa

20 June 2018 in Disease Markers
Verified
Journal Article
Open access
PDF file
HHHyundoo Hwang
Hyundoo Hwang
BHBoo-Young Hwang
Boo-Young Hwang
JBJuan Bueno
Juan Bueno

1 June 2010 in Brazilian Journal of Microbiology
Verified
Journal Article
Open access
PDF file
JSJuan Gabriel Bueno Sánchez
Juan Gabriel Bueno Sánchez
Vladimir V. KouznetsovVladimir V. Kouznetsov
Vladimir V. Kouznetsov
The emergence of multidrug-resistant strains of Mycobacterium tuberculosis underscores the need of continuous developments on new and efficient methods to determine the susceptibility of isolates of M. tuberculosis in the search for novel antimicrobial agents. Natural products constitute an important source of new drugs, but design and implementation of antimycobacterial susceptibility testing methods are necessary for evaluate the different extracts and compounds. A number of biological assay methodologies are in current use, ranging from the classical disk diffusion and broth dilution assay format, to radiorespirometric (BACTEC), dye-based, and fluorescent/luminescence reporter assays. This review presents an analysis on the in vitro susceptibility testing methods developed for determinate antitubercular activity in natural products and related compounds (semi-synthetic natural products and natural products-derived compounds) and the criteria to select the adequate method for determination of biological activity of new natural products.

1 March 2009 in Biomédica
Verified
Journal Article
Open access
PDF file
JBJuan Gabriel Bueno-Sánchez
Juan Gabriel Bueno-Sánchez
JMJairo René Martínez-Morales
Jairo René Martínez-Morales
ESElena E. Stashenko
Elena E. Stashenko
WRWellman Ribón
Wellman Ribón
Actividad antituberculosa de plantas colombianas

1 March 2014 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JQJairo Quiroga
Jairo Quiroga
YDYurina Diaz
Yurina Diaz
JBJuan Bueno
Juan Bueno
BIBraulio Insuasty
Braulio Insuasty
Rodrigo AboniaRodrigo Abonia
Rodrigo Abonia
JCJusto Cobo
Justo Cobo

1 November 2011 in Natural Product Communications
Verified
Journal Article
Open access
PDF file
JBJuan Bueno
Juan Bueno
PEPatricia Escobar
Patricia Escobar
JMJairo René Martínez
Jairo René Martínez
SLSandra Milena Leal
Sandra Milena Leal
ESElena Stashenko
Elena Stashenko
Tuberculosis (TB) is the most ancient epidemic disease in the world and a serious opportunistic disease in HIV/AIDS patients. The increase in multidrug resistant Mycobacterium tuberculosis (MDR-TB, XDR-TB) demands the search for novel antimycobacterial drugs. Essential oils (EOs) have been widely used in medicine and some EOs and their major components have been shown to be active against M. tuberculosis. The aim of this work was to evaluate the antimycobacterial and cell toxicity activities of three EOs derived from Salvia aratocensis, Turnera diffusa and Lippia americana, aromatics plants collected in Colombia. The EOs were isolated by hydrodistillation and analyzed by GC/MS techniques. The EOs were tested against 15 Mycobacterium spp using a colorimetric macrodilution method and against mammalian Vero and THP-1 cells by MTT. The activity was expressed as minimal concentration in μg/mL that inhibits growth, and the concentration that is cytotoxic for 50 or 90% of the cells (CC50 and CC90). The major components were epi-α-cadinol (20.1%) and 1,10-di- epi-cubenol (14.2%) for Salvia aratocensis; drima-7,9(11)-diene (22.9%) and viridiflorene (6.6%) for Turnera diffusa; and germacrene D (15.4%) and trans-β- caryophyllene (11.3%) for Lippia americana. The most active EO was obtained from S. aratocensis, with MIC values below 125 μg mL−1 for M. tuberculosis Beijing genotype strains, and 200 to 500 μg mL−1 for nontuberculous mycobacterial strains. The EOs were either partially or non toxic to Vero and THP-1 mammalian cells with CC50 values from 30 to >100 μg mL−1, and a CC90 >100 μg mL−1. The EOs obtained from the three aromatic Colombian plants are an important source of potential compounds against TB. Future studies using the major EO components are recommended.